SAB Biotherapeutics Inc. announced the appointment of four immunotherapy specialists to its newly formed Scientific Advisory Board. These globally recognized scientists and physicians will serve as a strategic resource to SAB as it develops therapeutic applications for its antibody production technology. The Board is comprised of a team of distinguished immunotherapy leaders with diverse perspectives to provide valuable scientific and clinical insights, in infectious disease, oncology, viral infections and autoimmune disorders, as the Company advances antibody products through clinical trials.

The members of the company's new Scientific Advisory Board include: James Robl, Ph.D., Scientist and Biotech Entrepreneur James Robl, Ph.D.: is an internationally recognized scientist and entrepreneur specialized in transgenic animals and cloning in cattle. He is a former professor at the University of Massachusetts-Amherst and founder of the project that led to the underlying technologies of the DiversitAb Platform antibody production technology and Tc Bovine™. Dr. Robl will serve as the Chairman of the advisory board.

Arturo Casadevall, M.D., Ph.D., Johns Hopkins Bloomberg School of Public Health. Dr. Casadevall is an internationally recognized expert in infectious disease research, with a focus on fungal and bacterial pathogenesis and basic immunology of antibody structure-function. Michael Haller, M.D., MS-CI, University of Florida Medical Center: Dr. Haller is Associate Professor of Pediatrics at the University of Florida Medical Center and an active investigator in the NIH funded Type 1 diabetes TrialNet and The Environmental Determinants of Diabetes in Youth (TEDDY) study.

Frederick Hayden, M.D., University of Virginia School of Medicine: Dr. Hayden is Richardson Professor of Clinical Virology in the Department of Medicine at the University of Virginia School of Medicine. He is internationally recognized for his work with the application of antiviral agents for the prevention and treatment of respiratory viral infections, including influenza and rhinovirus infections and other respiratory viral diseases.